Takeda Pharmaceutical (NYSE:TAK) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Takeda Pharmaceutical (NYSE:TAK) from a hold rating to a strong-buy rating in a report released on Saturday.

TAK has been the topic of a number of other reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. Morgan Stanley assumed coverage on Takeda Pharmaceutical in a research note on Tuesday, January 13th. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Takeda Pharmaceutical presently has an average rating of “Hold”.

Takeda Pharmaceutical Trading Up 1.5%

NYSE TAK opened at $17.49 on Friday. Takeda Pharmaceutical has a one year low of $12.99 and a one year high of $17.55. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.65 and a current ratio of 1.19. The company has a market capitalization of $55.64 billion, a price-to-earnings ratio of 72.86 and a beta of 0.02. The company’s 50-day simple moving average is $15.47 and its two-hundred day simple moving average is $14.83.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, January 29th. The company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.07). The business had revenue of $7.76 billion for the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. Equities analysts forecast that Takeda Pharmaceutical will post 1.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Private Trust Co. NA grew its stake in shares of Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after acquiring an additional 783 shares during the last quarter. Twin Peaks Wealth Advisors LLC purchased a new position in shares of Takeda Pharmaceutical in the 2nd quarter valued at approximately $28,000. Evelyn Partners Investment Management LLP boosted its stake in Takeda Pharmaceutical by 163.4% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 2,515 shares of the company’s stock worth $39,000 after purchasing an additional 1,560 shares in the last quarter. True Wealth Design LLC grew its position in Takeda Pharmaceutical by 1,262.3% during the 3rd quarter. True Wealth Design LLC now owns 2,711 shares of the company’s stock worth $40,000 after purchasing an additional 2,512 shares during the last quarter. Finally, NewSquare Capital LLC increased its stake in Takeda Pharmaceutical by 182.4% during the 2nd quarter. NewSquare Capital LLC now owns 3,451 shares of the company’s stock valued at $53,000 after purchasing an additional 2,229 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.